A number of companies are ready to make money off of Danish men in need of medicinal help in the bedroom. Pfizer’s Danish patent on the anti-impotence drug Viagra, containing the active substance sildenafil citrate, will expire on July 24 following 15 years of market exclusivity, and so far 15 companies have had marketing approvals for generic versions approved by the Danish medicines authorities.
The only Danish company to venture into this area is the parallel importer and generics manufacturer, Orifram. Orifarm has experience with selling generic versions of Viagra on the Finnish market where the drug has already lost patent. Aside from the single Danish company, it is major international generics giants, such as Teva, Actavis, Mylan and Novartis’ generics subsidiary, Sandoz, which are looking to enter the market.